Dow's CFO cites $1.1B of quarterly free cash flow and no big debt maturities until 2029, while Union Pacific's fuel bill jumped 69%. Both lean on self-help and balance-sheet strength. Figures come from SEC filings and earnings-call transcripts; the transcript source is reliable only about 60% of the time.

Via News tracked a US-led fintech wave, from retail event contracts to AI-agent identity startups. Little of it is European, and the dossier names no EU regulator. We lead with Robinhood's SEC-checked figures and flag where sources diverge or are weak.

Salesforce, ServiceNow and others are rebuilding around autonomous AI agents, and governance is becoming the selling point. The dossier holds no EU-specific regulatory facts, so we say so. What it does hold is SEC-verified Salesforce financials and primary announcements.

Europe's drug regulator issued positive opinions on RASONQUE, Libtayo dosing and Trodelvy plus Keytruda this summer and autumn, just before ESMO opens in Madrid. SEC-checked figures for Summit Therapeutics show what the pipeline costs. We flag where the evidence is thin or the sources are weak.

Analysts turned more bullish on Palantir in mid-October 2026 while J.P. Morgan's lead defence analyst downgraded Leidos and warned of a weak sector. The dossier holds little European regulatory material, so we say so, and set out what was said, by whom, and how reliable the sources are.

EU regulators backed a new Libtayo dosing schedule and a Trodelvy-Keytruda combination, while US dates for Summit's ivonescimab loom. AstraZeneca's AI drug-design vision rests on forecasts, not results. Summit's checked SEC filings show the cost of a late-stage bet.

Analysts are upgrading Palantir while J.P. Morgan warns on defence stocks. The dossier holds little European-specific evidence, so we say so. We separate verified figures, analyst opinion and our own reading, and flag where the sources are weak.

EU regulators are backing newer cancer treatments, and AI is billed as the long-term engine. But the one company with checked SEC figures, Summit Therapeutics, lost $1.08 billion in FY2025 with no revenue. Several AI claims are forecasts from a source that failed our reliability check.

AI spending is spreading from chips to networking, physical-world data and customer-service software. Nvidia's audited cost of sales shows how fast. The dossier says little about EU rules, and safety scrutiny of OpenAI is rising. Verified filings are separated from company claims.

SAP, Zeta and others are launching agent platforms, while the smaller deals show money flowing to the layers that keep agents in check. Our dossier has little on EU regulation, so we say so. It does contain a clear argument that rules must be enforced by the system, and a warning not to trust AI with finance arithmetic.

A CHMP opinion for Trodelvy, a German-first Optune Pax launch and real-world German data on mogamulizumab give Europe its own oncology story in a US-heavy October. Summit's SEC-verified accounts show how costly the biggest catalyst, ivonescimab, is to reach. Some sources here fared poorly in our reliability checks.

A French networking tie-up and a Dutch equipment maker sit at the European edge of an AI-driven memory and interconnect squeeze. SEC-verified Micron filings show how fast its spending has grown. We separate the checked figures from analyst opinion and flag where the sources are weak.

Three oncology storylines are converging: new-modality drugs nearing decisions, AI-built biologics, and a care-delivery buyout. For European readers the clearest signals are an EMA committee opinion and a Swiss-based device maker's EU launch. Summit's checked SEC filings show what a late-stage bet costs. Source reliability is flagged throughout.

Verified SEC data show Micron's annual capital spending nearly doubled to $15.9bn in fiscal 2025. Meanwhile Nvidia is locking down memory supply, and France's Kalray and Bull are pursuing AI networking. Much of the supporting reporting is only partly reliable, and we show where.

The EU regulator has backed a new first-line breast cancer combination and Novocure has won a CE Mark, while US decisions on ivonescimab and a personalised mRNA vaccine arrive by 14 November. Merck's SEC-verified numbers show cash moving sharply and capex falling. Our sources vary widely in reliability, and we say where.

A European regulator backed a new first-line breast cancer combination, and a Swiss-based device maker reported record revenue while opening a German launch. Behind both sits a pipeline built on AI, mRNA and antibody-drug combinations. We separate what is verified from what is still a claim.

SEC-filed figures show Micron's capital spending almost doubled in a year and its cash pile reached $25 billion. Analysts are bullish on AI-infrastructure names but flag stretched valuations. The dossier holds little EU regulatory material, and we say so.

SEC-filed figures show Micron's capital spending nearly doubled in a year, while Europe's visible role is ASML's rally and a Kalray–Bull networking pact. Analysts' 33% to 49% upside calls come from a source whose claims held up only 22% of the time in our checks.

A survey reported by MIT Technology Review finds every respondent plans to use agentic AI within two years, yet AI reaches only about 45% of company data and only about half trust their agents. Deals from Manulife, Box and Nvidia show where the money is going. That source scores poorly on our reliability check, so we flag it.

Mattel, Verra Mobility, BellRing and Brown-Forman have all named or are seeking new chief executives, while boards from Dublin to Amsterdam run shareholder-vote processes. The dossier is thin on Heineken and EU regulation, so we report what it supports. The picture is calm on the surface, and Brown-Forman and Kneat are the exceptions.

Agentic AI is pulling Big Tech, venture money and incumbents into enterprise software. Via News traced this to checked filings and interviews, not forecasts. The European evidence is thin but concrete: Paris-listed 74Software's buyback and Europe-based Light. Governance, not model quality, looks like the limit.

A survey says every organisation will use agentic AI within two years, with company data as the bottleneck. That survey source scores 0% on our reliability check, so we treat it as a claim to test. Verified Nvidia filings and named company deals give firmer ground. Europe's role in this material is thin, and we say so.

Europe's regulator has backed a new first-line breast cancer combination, and a Swiss-based device maker posted record revenue. The AI-biologics story behind the optimism rests on a source where none of 11 checked claims held up. Here is what the checked data supports.

A survey reported by MIT Technology Review says 100% of respondents plan to use agentic AI within two years, yet the supporting data is weaker than the headline. The source has a poor measured reliability record. Nvidia's audited accounts and the Manulife, Box and Nomura announcements are firmer ground.

SEC filings show Micron's quarterly capital spending rose from $1.8bn to $5.4bn in two years and its cash pile reached $25bn. Analyst enthusiasm is heavily concentrated in AI infrastructure, and the sources behind much of it have mixed track records. Little of the dossier is explicitly European, and we say where.